Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma
Weekly Administration of Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer
Sponsor: Hellenic Oncology Research Group
A PHASE1/PHASE2 clinical study on Ovarian Cancer, this trial is completed. The trial is conducted by Hellenic Oncology Research Group and has accumulated 6 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
First recorded
Jun 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hellenic Oncology Research Group
- University Hospital of Crete
For direct contact, visit the study record on ClinicalTrials.gov .